Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (4)

Search Parameters:
Keywords = glycine transporter inhibitor combination

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
20 pages, 20063 KB  
Article
Sarcosine Remodels DNA Methylation-Linked Transcriptional Networks During Epileptogenesis in the Rat Rapid Hippocampal Kindling Model
by Nicole Ferris, Lan Phung, Wakaba Omi, Guoku Hu and Hai-Ying Shen
Int. J. Mol. Sci. 2026, 27(17), 7938; https://doi.org/10.3390/ijms27177938 - 6 Sep 2026
Abstract
DNA methylation is implicated in epileptogenesis. Sarcosine, a glycine transporter 1 (GlyT1) inhibitor and methyl donor, attenuates behavioral progression during rapid hippocampal kindling and alters hippocampal DNA methylation, but its locus-specific epigenetic effects remain poorly understood. Here, reduced representation bisulfite sequencing (RRBS) was [...] Read more.
DNA methylation is implicated in epileptogenesis. Sarcosine, a glycine transporter 1 (GlyT1) inhibitor and methyl donor, attenuates behavioral progression during rapid hippocampal kindling and alters hippocampal DNA methylation, but its locus-specific epigenetic effects remain poorly understood. Here, reduced representation bisulfite sequencing (RRBS) was combined with targeted gene expression analysis in the hippocampi of sarcosine-treated kindled rats. RRBS identified 563, 533, and 390 differentially methylated regions (DMRs), corresponding to 521, 499, and 374 DMR-associated genes, in vehicle-kindled versus sham (vKD vs. vSH), sarcosine-kindled versus sham (sKD vs. vSH), and sarcosine-kindled versus vehicle-kindled (sKD vs. vKD) comparisons, respectively. Pathway enrichment analysis identified 217 significantly affected pathways, including glutamatergic signaling, extracellular matrix (ECM) organization, chromatin regulation, axon guidance, and apoptotic processes. Eleven candidate genes involved in epigenetic regulation, excitatory neurotransmission, and ECM remodeling were selected for transcriptional validation. All 11 genes were significantly upregulated in kindled hippocampi, whereas sarcosine was associated with reduced expression relative to vehicle-kindled rats for eight genes (Hdac9, Fos, Smad7, Unc5a, Grik2, Gpr37l1, Cacna2d2, and Yy1). Collectively, these findings indicate that sarcosine remodels DNA methylation-associated transcriptional networks during rapid hippocampal kindling and support GlyT1 inhibition as a potential disease-modifying approach in experimental epileptogenesis. Full article
Show Figures

Graphical abstract

17 pages, 2760 KB  
Article
Glycine Transporter 1 Inhibitors Minimize the Analgesic Tolerance to Morphine
by Anna Rita Galambos, Nariman Essmat, Péter P. Lakatos, Edina Szücs, Imre Boldizsár, Sarah Kadhim Abbood, Dávid Á. Karádi, Judit Mária Kirchlechner-Farkas, Kornél Király, Sándor Benyhe, Pál Riba, Tamás Tábi, Laszlo G. Harsing, Ferenc Zádor and Mahmoud Al-Khrasani
Int. J. Mol. Sci. 2024, 25(20), 11136; https://doi.org/10.3390/ijms252011136 - 17 Oct 2024
Cited by 6 | Viewed by 3556
Abstract
Opioid analgesic tolerance (OAT), among other central side effects, limits opioids’ indispensable clinical use for managing chronic pain. Therefore, there is an existing unmet medical need to prevent OAT. Extrasynaptic N-methyl D-aspartate receptors (NMDARs) containing GluN2B subunit blockers delay OAT, indicating the involvement [...] Read more.
Opioid analgesic tolerance (OAT), among other central side effects, limits opioids’ indispensable clinical use for managing chronic pain. Therefore, there is an existing unmet medical need to prevent OAT. Extrasynaptic N-methyl D-aspartate receptors (NMDARs) containing GluN2B subunit blockers delay OAT, indicating the involvement of glutamate in OAT. Glycine acts as a co-agonist on NMDARs, and glycine transporters (GlyTs), particularly GlyT-1 inhibitors, could affect the NMDAR pathways related to OAT. Chronic subcutaneous treatments with morphine and NFPS, a GlyT-1 inhibitor, reduced morphine antinociceptive tolerance (MAT) in the rat tail-flick assay, a thermal pain model. In spinal tissues of rats treated with a morphine–NFPS combination, NFPS alone, or vehicle-comparable changes in µ-opioid receptor activation, protein and mRNA expressions were seen. Yet, no changes were observed in GluN2B mRNA levels. An increase was observed in glycine and glutamate contents of cerebrospinal fluids from animals treated with a morphine–NFPS combination and morphine, respectively. Finally, GlyT-1 inhibitors are likely to delay MAT by mechanisms relying on NMDARs functioning rather than an increase in opioid efficacy. This study, to the best of our knowledge, shows for the first time the impact of GlyT-1 inhibitors on MAT. Nevertheless, future studies are required to decipher the exact mechanisms. Full article
Show Figures

Figure 1

15 pages, 4424 KB  
Article
The Transport and Uptake of Resveratrol Mediated via Glucose Transporter 1 and Its Antioxidant Effect in Caco-2 Cells
by Zhen-Dong Zhang, Qi Tao, Li-Xia Bai, Zhe Qin, Xi-Wang Liu, Shi-Hong Li, Ya-Jun Yang, Wen-Bo Ge and Jian-Yong Li
Molecules 2023, 28(12), 4569; https://doi.org/10.3390/molecules28124569 - 6 Jun 2023
Cited by 9 | Viewed by 4026
Abstract
Resveratrol has anti-inflammatory, anti-cancer, and anti-aging pharmacological activities. There is currently a gap in academic research regarding the uptake, transport, and reduction of H2O2-induced oxidative damage of resveratrol in the Caco-2 cell model. This study investigated the role of [...] Read more.
Resveratrol has anti-inflammatory, anti-cancer, and anti-aging pharmacological activities. There is currently a gap in academic research regarding the uptake, transport, and reduction of H2O2-induced oxidative damage of resveratrol in the Caco-2 cell model. This study investigated the role of resveratrol in the uptake, transport, and alleviation of H2O2-induced oxidative damage in Caco-2 cells. In the Caco-2 cell transport model, it was observed that the uptake and transport of resveratrol (10, 20, 40, and 80 μM) were time dependent and concentration dependent. Different temperatures (37 °C vs. 4 °C) could significantly affect the uptake and transportation of resveratrol. The apical to basolateral transport of resveratrol was markedly reduced by STF-31, a GLUT1 inhibitor, and siRNA intervention. Furthermore, resveratrol pretreatment (80 μM) improves the viability of Caco-2 cells induced by H2O2. In a cellular metabolite analysis combined with ultra-high performance liquid chromatography-tandem mass spectrometry, 21 metabolites were identified as differentials. These differential metabolites belong to the urea cycle, arginine and proline metabolism, glycine and serine metabolism, ammonia recycling, aspartate metabolism, glutathione metabolism, and other metabolic pathways. The transport, uptake, and metabolism of resveratrol suggest that oral resveratrol could prevent intestinal diseases caused by oxidative stress. Full article
(This article belongs to the Special Issue Natural Products in the Antioxidant Drug Discovery Process)
Show Figures

Figure 1

15 pages, 5261 KB  
Article
Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model
by Amir Mohammadzadeh, Péter P. Lakatos, Mihály Balogh, Ferenc Zádor, Dávid Árpád Karádi, Zoltán S. Zádori, Kornél Király, Anna Rita Galambos, Szilvia Barsi, Pál Riba, Sándor Benyhe, László Köles, Tamás Tábi, Éva Szökő, Laszlo G. Harsing and Mahmoud Al-Khrasani
Int. J. Mol. Sci. 2021, 22(5), 2479; https://doi.org/10.3390/ijms22052479 - 1 Mar 2021
Cited by 20 | Viewed by 4240
Abstract
The limited effect of current medications on neuropathic pain (NP) has initiated large efforts to develop effective treatments. Animal studies showed that glycine transporter (GlyT) inhibitors are promising analgesics in NP, though concerns regarding adverse effects were raised. We aimed to study NFPS [...] Read more.
The limited effect of current medications on neuropathic pain (NP) has initiated large efforts to develop effective treatments. Animal studies showed that glycine transporter (GlyT) inhibitors are promising analgesics in NP, though concerns regarding adverse effects were raised. We aimed to study NFPS and Org-25543, GlyT-1 and GlyT-2 inhibitors, respectively and their combination in rat mononeuropathic pain evoked by partial sciatic nerve ligation. Cerebrospinal fluid (CSF) glycine content was also determined by capillary electrophoresis. Subcutaneous (s.c.) 4 mg/kg NFPS or Org-25543 showed analgesia following acute administration (30–60 min). Small doses of each compound failed to produce antiallodynia up to 180 min after the acute administration. However, NFPS (1 mg/kg) produced antiallodynia after four days of treatment. Co-treatment with subanalgesic doses of NFPS (1 mg/kg) and Org-25543 (2 mg/kg) produced analgesia at 60 min and thereafter meanwhile increased significantly the CSF glycine content. This combination alleviated NP without affecting motor function. Test compounds failed to activate G-proteins in spinal cord. To the best of our knowledge for the first time we demonstrated augmented analgesia by combining GlyT-1 and 2 inhibitors. Increased CSF glycine content supports involvement of glycinergic system. Combining selective GlyT inhibitors or developing non-selective GlyT inhibitors might have therapeutic value in NP. Full article
(This article belongs to the Special Issue Molecular Links between Sensory Nerves, Inflammation, and Pain)
Show Figures

Figure 1

Back to TopTop